Promed Bioscience is a Cypriot biotech company that produces highly purified, medical-grade collagen scaffolds designed to serve as ‘bridges’ that help the body regenerate its own tissue. Its proprietary technology underpins 3D bioprinting and broader regenerative medicine platforms, and its collagen is already incorporated into an FDA-approved medical device for lymphatic vessel regeneration through a partnership with a Stanford spin-off. Commercial traction includes more than €30 million in supply agreements with two leading South Korean medical-implant manufacturers, plus additional collaborations across Asia, Europe, and the Americas. The company is now scaling to industrial-level production, investing in state-of-the-art protein extraction and quality-control equipment to meet rising global demand. Fresh capital will be directed toward expanding manufacturing capacity, accelerating U.S. commercial activities, and deepening international market penetration. Promed positions itself as a trusted partner that can deliver to stringent global regulatory standards while continuing R&D on next-generation biomaterials.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025